# Biotech Daily Digest â€” 2025-12-13

**10 items from 2 sources**

## Summary by Source

- Endpoints News: 6 items
- Fierce Biotech: 4 items


## Endpoints News

- **[Eli Lillyâ€™s triple-G obesity readout; The latest Endpoints 100 results; Public biotechs cash in; and more](https://endpoints.news/eli-lillys-triple-g-obesity-readout-the-latest-endpoints-100-results-public-biotechs-cash-in-and-more/)**  
  _Sat, 13 Dec 2025 11:00:18 +0000_  
  Welcome back to another edition of Endpoints Weekly. Weâ€™re barreling toward the holiday season, which means itâ€™s time for an early programming note: Our newsletters will go dark between Dec. 24 and Jan. 1. But ...

- **[A 2-speed payer transformation is underway](https://endpoints.news/a-2-speed-payer-transformation-is-underway/)**  
  _Fri, 12 Dec 2025 17:29:45 +0000_  
  Health insurers are facing two colliding forces heading into 2026: Medical costs are challenging the way they do business, and major technology shifts are finally starting to reshape the industry.

 Patrick Finn, senior partner at ...

- **[CHMP calls to reject Anavex's Alzheimerâ€™s pill over impurities, side effects and weak efficacy](https://endpoints.news/chmp-calls-to-reject-anavex-alzheimers-pill-over-impurities-side-effects-and-weak-efficacy/)**  
  _Fri, 12 Dec 2025 17:27:18 +0000_  
  As part of a batch of recommendations issued Friday, the European Medicines Agencyâ€™s human medicines committee (CHMP) recommended rejecting Anavexâ€™s Alzheimerâ€™s disease drug, issuing a scathing review of the pill's safety and efficacy issues.  ...

- **[#SABCS25: Celcuity further details Phase 3 win; Relayâ€™s PI3KÎ± inhibitorâ€™s consistent performance; and more](https://endpoints.news/sabcs25-celcuity-further-details-phase-3-win-relays-pi3k%ce%b1-inhibitors-consistent-performance-and-more/)**  
  _Fri, 12 Dec 2025 16:20:58 +0000_  
  Roche and BioNTech stole the show at this yearâ€™s San Antonio Breast Cancer Symposium.

 The Swiss drugmaker unveiled Phase 3 data for its oral SERD giredestrant, showing the drug slashed the risk ...

- **[Arcus, Gilead report Phase 3 TIGIT failure in upper GI cancers](https://endpoints.news/arcus-gilead-report-phase-3-tigit-failure-in-upper-gi-cancers/)**  
  _Fri, 12 Dec 2025 15:59:53 +0000_  
  Another TIGIT program has failed in the clinic, this time in a Phase 3 study.

 Arcus and Gilead said on Friday that their anti-TIGIT antibody domvanalimab, when combined with an experimental anti-PD-1 and chemotherapy, did ...

- **[Innoventâ€™s obesity drug data in adolescents; Everest gets rights to PCSK9 inhibitor](https://endpoints.news/innovents-obesity-drug-data-in-adolescents-everest-gets-rights-to-pcsk9-inhibitor/)**  
  _Fri, 12 Dec 2025 14:36:09 +0000_  
  Plus, news about BioCryst, Cycle Pharma, Applied Therapeutics, Contineum Therapeutics, Juncell Therapeutics, Cosette and Mayne Pharma:

 ðŸ“Š Innoventâ€™s mazdutide shows early promise in adolescents: The injected GLP-1/glucagon agonist allowed body weight and BMI reductions ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/medtech/gao-probe-finds-understaffed-fda-putting-medical-device-recall-work-back-burner" hreflang="en">GAO probe finds understaffed FDA putting some medical device recall work on the 'back burner'</a>](https://www.fiercebiotech.com/medtech/gao-probe-finds-understaffed-fda-putting-medical-device-recall-work-back-burner)**  
  _Dec 12, 2025 2:36pm_  
  The FDAâ€™s oversight of medical device recalls continues to be plagued by staffing challenges, resulting in lengthy response times, according to a report from the U.S. Government Accountability Office.

- **[<a href="https://www.fiercebiotech.com/biotech/obesity-biotech-zealand-seeks-partners-take-therapies-directly-brain" hreflang="en">Obesity biotech Zealand seeks partners to â€˜take therapies directly to the brainâ€™</a>](https://www.fiercebiotech.com/biotech/obesity-biotech-zealand-seeks-partners-take-therapies-directly-brain)**  
  _Dec 12, 2025 9:45am_  
  Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the companyâ€™s long-term success.

- **[<a href="https://www.fiercebiotech.com/biotech/2026-outlook-biotech-poised-outperform-bear-markets-21-24-analyst-says" hreflang="en">2026 outlook: Biotech poised to outperform bear markets of â€™21-24, analyst says</a>](https://www.fiercebiotech.com/biotech/2026-outlook-biotech-poised-outperform-bear-markets-21-24-analyst-says)**  
  _Dec 12, 2025 10:30am_  
  After a year marked by dramatic ups and downs, William Blair analysts say 2026 could carry forward the industryâ€™s current momentumâ€”as long as strong clinical data continue to be rewarded and companies can bring drugs to market without major government pricing regulations.

- **[<a href="https://www.fiercebiotech.com/biotech/arcus-halts-gilead-partnered-tigit-trials-biotech-reworks-rd-focus" hreflang="en">Arcus discontinues Gilead-partnered TIGIT trials due to futility</a>](https://www.fiercebiotech.com/biotech/arcus-halts-gilead-partnered-tigit-trials-biotech-reworks-rd-focus)**  
  _Dec 12, 2025 9:25am_  
  A key late-stage trial of Arcus Biosciences and Gileadâ€™s anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several trials of the drug.
